Who we are
InnovaVector is a full-service Contract Development and Manufacturing Organization (CDMO) that offers innovative solutions for the development, production and release of AAV vectors for non-clinical and clinical use. InnovaVector is a lively and international working community with rapidly expanding career opportunities, that people aspire to work for. We are located in subtropical Campania-region in Pozzuoli (Naples) by the Mediterranean sea shore and surrounded by ancient architectural recoveries.
Our mission is to become a leading provider of high quality Adeno-Associated Viral (AAV) vectors for non- clinical and clinical studies.
In vivo gene therapy with adeno-associated viral (AAV) vectors is delivering on its promise as an effective therapeutic strategy given the growing number of clinical trials using this vector platform and the fact that among the first gene therapy products that have recently reached the market in the US and/or the EU three are AAV-based (Glybera, Luxturna and Zolgensma). One major limitation to the clinical development of AAV is the availability of GMP material for clinical trials. InnovaVector has been created to meet the growing demand for GMP AAV batches, accelerating the transfer of existing excellent research on gene therapy from academia to the market and facilitating the development path of new gene therapies.
InnovaVector has been built on the expertise in AAV production, purification and characterisation established at Telethon Institute of Genetics and Medicine (TIGEM), Naples, Italy, in particular within its AAV Vector Core.
TIGEM/ InnovaVector AAV Vector Core has over twenty years experience in the release of research-grade lots of AAV on all serotypes in preclinical studies in all kind of models.